Detoxification Pathways (Phase I-III, Glutathione, Binders) — References

Navigation

• Parent Topic: Detoxification Pathways (Phase I-III, Glutathione, Binders)
• Reference Hub: 04 - Longevity & Environment References MOC

---

Primary Literature Dossier

1. Egner et al. (2014) — Rapid and Sustainable Detoxication of Airborne Pollutants by Sulforaphane: A 12-Week Randomized Clinical Trial

• Citation: Egner PA, Chen JG, Zarth AT, Ng DK, Wang JB, Kensler KH, Jacobson LP, Muñoz A, Johnson JL, Groopman JD, Fahey JW, Talalay P, Zhu J, Chen TY, Qian GS, Carmella SG, Hecht SS, Kensler TW. Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China. Cancer Prevention Research (Phila). 2014 Aug;7(8):813-823.
• Identifiers: PMID: 24913818 (PubMed · Europe PMC) | DOI: 10.1158/1940-6207.CAPR-14-0103 (DOI · SciDB · Scholar)
• Study Design & Sample Size: 12-week randomized, placebo-controlled clinical trial ($n=291$ adult men and women in Qidong, China randomized to consume a standardized broccoli sprout beverage delivering $600\mu \text{mol}$ glucoraphanin + $40\mu \text{mol}$ (~$7.1\text{ mg}$) active sulforaphane daily vs. placebo beverage, with serial LC-MS/MS urinary mercapturic acid conjugate assays).
• Key Quantitative Outcomes:
  • Sulforaphane administration induced a rapid, sustained +61% increase in the urinary excretion of $S$-phenylmercapturic acid (SPMA, the glutathione-derived Phase II conjugate of carcinogenic benzene) ($p=0.001$) and a +23% increase in 3-hydroxypropylmercapturic acid (3-HPMA, the glutathione conjugate of acrolein) ($p<0.01$).
  • Enhanced Phase II detoxification began within 24 hours of the first dose and did not attenuate over the full 84-day intervention, regardless of GSTM1 or GSTT1 genotype.

2. Kumar et al. (2023) — Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Mitochondrial Dysfunction, and Hallmarks of Aging: A Randomized Clinical Trial

• Citation: Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The Journals of Gerontology: Series A. 2023 Jan 26;78(1):75-89.
• Identifiers: PMID: 35975308 (PubMed · Europe PMC) | DOI: 10.1093/gerona/glac135 (DOI · SciDB · Scholar)
• Study Design & Sample Size: 16-week randomized, double-blind, placebo-controlled clinical trial ($n=24$ older adults aged 61–80 years randomized to GlyNAC [$100\text{ mg/kg/day}$ glycine + $100\text{ mg/kg/day}$ NAC] vs. isonitrogenous alanine placebo for 16 weeks, compared against $n=12$ young adult reference controls aged 21–40 years, with skeletal muscle biopsies and stable-isotope tracer kinetics).
• Key Quantitative Outcomes:
  • Older adults at baseline had 66% lower muscle GSH and 55% lower RBC GSH than young adults; 16 weeks of GlyNAC increased RBC GSH by +121% ($p<0.0001$) and skeletal muscle GSH by +164% ($p<0.0001$), fully normalizing intracellular glutathione to young-adult levels.
  • Plasma TBARS and F2-isoprostanes (oxidative stress) fell by -72% ($p<0.0001$), mitochondrial fatty acid oxidation and $\text{PGC-1}\alpha /\text{PINK1}$ mitophagy proteins recovered, $\text{HOMA-IR}$ decreased by -64%, $\text{IL-6}$ fell by -78%, $\text{TNF-}\alpha$ fell by -54%, $\text{hs-CRP}$ fell by -41%, endothelial $\text{sICAM1/sVCAM1}$ dropped significantly, gait speed increased to match young adults ($p<0.001$), and systolic BP dropped by $-7\text{ mmHg}$.

3. Zhao et al. (2006) — Integrative Clinical Trial on the Effect of Modified Citrus Pectin on Urinary Excretion of Toxic Elements (As, Cd, Pb, Hg)

• Citation: Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytotherapy Research. 2006 Oct;20(10):859-864. (Companion pediatric lead clearance trial: Zhao ZY, Liang L, Fan X, et al. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Alternative Therapies in Health and Medicine. 2008 Jul-Aug;14(4):34-38; PMID 18616067 (PubMed)).
• Identifiers: PMID: 16835878 (PubMed · Europe PMC) (10.1002/ptr.1953 (DOI · SciDB)) & PMID: 18616067 (PubMed · Europe PMC)
• Study Design & Sample Size: Prospective human clinical trials ($n=8$ healthy adults given $15\text{ g/day}$ low-molecular-weight [$10\text{–}20\text{ kDa}$, $<10\%$ esterification] Modified Citrus Pectin [MCP] for 5 days; plus $n=7$ hospitalized patients with toxic blood lead $>20\mu \text{g/dL}$ treated for 2–4 weeks).
• Key Quantitative Outcomes:
  • In healthy adults, 24-hour urinary excretion of Arsenic increased by +130% ($p<0.05$) on Day 1 and Cadmium increased by +150% ($p<0.05$) by Day 6, without increasing urinary loss of essential minerals (${\text{Ca}}^{2+},{\text{Mg}}^{2+},{\text{Zn}}^{2+},\text{Se}$).
  • In lead-exposed subjects, oral MCP decreased blood lead levels by -61% ($p=0.0016$) while increasing 24-hour urinary lead excretion by +132% to +560% ($p=0.0007$).

4. Kars et al. (2010) / Beuers et al. (2001) — Tauroursodeoxycholic Acid (TUDCA) Enhances Phase III Canalicular MRP2 Transporter Insertion and Human Insulin Sensitivity

• Citation: Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010 Aug;59(8):1899-1905. (Companion canalicular Phase III mechanism: Beuers U et al. Gastroenterology. 2001;120(2):400-410; PMID 11159881 (PubMed)).
• Identifiers: PMID: 20522594 (PubMed · Europe PMC) | DOI: 10.2337/db10-0308 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Randomized, double-blind, placebo-controlled human clinical trial ($n=20$ obese, insulin-resistant adults randomized to $1,750\text{ mg/day}$ oral TUDCA vs. placebo for 4 weeks with two-stage hyperinsulinemic-euglycemic clamps), paired with hepatocyte canalicular $\text{MRP2/BSEP}$ exocytosis studies.
• Key Quantitative Outcomes:
  • Oral TUDCA increased hepatic and skeletal muscle insulin sensitivity by ~30% ($p<0.05$) and increased muscle insulin-stimulated phosphorylated $\text{IRS-1}$ and $\text{Akt}$, while mechanistic hepatocyte studies proved TUDCA induces exocytic insertion of Phase III $\text{MRP2}$ and $\text{BSEP}$ efflux pumps into the canalicular membrane, doubling biliary clearance of glucuronidated and glutathione-conjugated substrates.